Vectura Group plc is a product development company focused on the development of a range of inhaled therapies, principally for the treatment of respiratory diseases. Our goal is to improve patients’ lives and generate value for our stakeholders.
Press releases
11 November 2008Date of announcement of Interim Results for the six months ended 30 September 2008
31 October 2008Vectura receives €7.5 million milestone from Boehringer Ingelheim
7 October 2008NVA237 Phase II results presented at ERS Meeting show efficacy and tolerability with potentially faster onset than tiotropium
Latest press releases
Next events
2-3 Dec 2008Piper Jaffray 20th Annual Health Care Conference, New York
Investor Calendar
